Detalles de la búsqueda
1.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Lancet Oncol;
2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38710187
2.
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Lancet;
402(10395): 41-53, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37331369
3.
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
Future Oncol;
2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38629456
4.
Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer.
Int J Clin Oncol;
2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38733489
5.
Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902).
Int J Clin Oncol;
29(2): 134-141, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38227090
6.
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.
Esophagus;
21(2): 102-110, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38240916
7.
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.
Esophagus;
2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38607538
8.
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
Br J Cancer;
129(6): 1032-1039, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37532830
9.
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.
Oncologist;
28(7): e565-e574, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35947993
10.
The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Cancer Immunol Immunother;
72(1): 169-181, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35776160
11.
Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer.
Ann Surg Oncol;
30(9): 5899-5907, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37316744
12.
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials.
Gastric Cancer;
26(5): 788-797, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335367
13.
Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106).
Int J Clin Oncol;
28(9): 1176-1182, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37418143
14.
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer.
Int J Clin Oncol;
28(11): 1501-1510, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37634209
15.
[A Case of Squamous Cell Carcinoma of the Lower Rectum].
Gan To Kagaku Ryoho;
50(4): 508-510, 2023 Apr.
Artículo
en Japonés
| MEDLINE | ID: mdl-37066470
16.
Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.
Br J Cancer;
126(11): 1555-1562, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35140339
17.
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Oncologist;
27(4): 251-e304, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35380725
18.
Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
BMC Cancer;
22(1): 773, 2022 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35840917
19.
Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
BMC Cancer;
22(1): 811, 2022 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35870893
20.
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Gastric Cancer;
25(1): 207-217, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480657